报价延迟最少15分钟:2026/08/02 00:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.83/--
|
|
企业价值
482.07M
|
| 资产负债 |
|
每股账面净值
3.56
|
| 现金流量 |
|
现金流量率
0.12
|
| 损益表 |
|
收益
386.01M
|
|
每股收益
3.23
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in onesegment. It has presence in Chinese Mainland, and Outside Chinese Mainland. |
